Reports Q1 revenue $31.59M , consensus $29.30M. David Bailey, President & CEO of OrthoPediatrics, commented, "I am extremely proud of our team and our ability to deliver better than expected overall growth to start the year off strong as the demand at children’s hospitals normalizes and they continue to manage staffing constraints. As we continue to develop and launch new products, we are seeing increased adoption of our product offering driving meaningful market share gains. Overall, I am very pleased with our progress and believe we are well-positioned strategically to continue our successful growth story."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- OrthoPediatrics continues sponsorship of 2023 POSNA annual meeting
- KIDS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OrthoPediatrics Corp. Announces Launch of RESPONSE™ 5.5/6.0 Cannulated Screw System
- OrthoPediatrics price target raised to $57 from $53 at Truist